MRI systems market will reach $9.27bn in 2020, according to new visiongain data.

31 August 2018
Pharma

A new report by visiongain, published in October 2016, forecasts that overall sales of magnetic resonance imaging (MRI) equipment will reach $9.27 billion worldwide in 2020. That revenue growth will continue strongly through to 2026, with rising demand for early and effective diagnostic procedures and advances in MRI technology.

That revenue prediction and others appear in Magnetic Resonance Imaging (MRI) Systems: Market Forecasts 2016-2026 – Report Assessing Medical Imaging Technologies Including High, Medium and Low-Field Equipment, Discussing Companies such as GE Healthcare, Toshiba, Siemens and Philips, with Revenue Predictions for Sales in the US, Japan, Germany, France, the UK, Italy, Spain, China, India, Brazil and Russia. Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations assess commercial prospects of industries and markets in healthcare and other fields.

Visiongain’s new study analyses events, progress and opportunities shaping the development, production and marketing of MRI products. That investigation shows multilevel revenue forecasting and qualitative assessments. The work also explores activities of companies providing MRI systems. The MRI devices market holds many commercial and technological opportunities from 2016, including rising sales in developed and emerging countries.

Revenue expansion for MRI products is driven by the rising incidence and prevalence of chronic diseases worldwide, which stimulates demand for improved medical diagnostic procedures in mature and rising national markets. Advances in MRI technology from 2016 to 2026 to improve efficacy and allow scans to be more accurate will benefit MRI companies and their industry, as well as healthcare providers and patients.

Aanchal Verma, a pharmaceutical and healthcare industry analyst in visiongain, said: “A key factor in the growth of the medical devices market is MRI systems, which has progressed rapidly in recent years owing primarily to an increased patient demand for early and effective diagnosis of diseases. Technological advances propelled the field of MRI, with new and innovative devices that scan regions of the body previously thought as difficult to image.

“The improving healthcare systems and economic prosperity in the emerging national markets will be a main driver of growth within the MRI devices market. Furthermore, the rise in incidence of chronic diseases, improvements in technology, awareness of early screening and the demand for improved diagnostics will fuel strong demand for MRI devices globally.”

Visiongain’s investigation shows forecasts at overall world market, submarket and national level. First that study gives individual revenue predictions to 2026 for four segments of the worldwide magnetic resonance imaging market:

• High-field equipment
• Medium-field systems
• Low-field devices
• Other related products.

The new report also breaks its overall world market forecast into individual revenue predictions to 2026 for these leading national markets:

• United States
• Japan
• Germany, France, United Kingdom, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC).

In addition the study assesses leading companies in that medical diagnostics and imaging field, including these organisations:

• GE Healthcare
• Toshiba
• Siemens
• Philips.

Magnetic Resonance Imaging (MRI) Systems: Market Forecasts 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers medical devices, diagnostics, pharmaceuticals, biotechnologies and outsourced services. Each year new and updated studies appear there, helping readers explore markets’ developments and potentials.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever